Faculty of Medicine, Macau University of Science and Technology, Taipa, China.
Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
J Integr Complement Med. 2024 Jan;30(1):11-24. doi: 10.1089/jicm.2022.0767. Epub 2023 Jul 11.
This meta-analysis evaluated the beneficial and potential adverse effects of Astragalus in the treatment of patients with type 2 diabetes mellitus (T2DM). The authors searched for randomized controlled trials of Astragalus treatment for patients with T2DM in the following databases: PubMed, Embase, Cochrane Library, China Knowledge Resource Integrated Database (CNKI), Wanfang Data, China Science and Technology Journal Database (CQVIP), and SinoMed. Two reviewers conducted independent selection of studies, data extraction, and coding, as well as the assessment of risk of bias in the studies included. Standard meta-analysis and, if appropriate, meta-regression were performed using the STATA, v.15.1, software. This meta-analysis encompasses 20 studies and a total of 953 participants. Compared to the control group (CG), the observation group (OG) decreased fasting plasma glucose (FPG) (WMD = -0.67, 95% CI: -1.13∼-0.20, = 0.005), 2 hours postprandial plasma glucose (2hPG) (WMD = -0.67 (95% CI: -1.13∼-0.20, =0.005), glycated hemoglobin A1C (HbA1c) (WMD = -0.93, 95% CI: -1.22∼-0.64, = 0.000), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD = -0.45, 95% CI: -0.99∼0.99, = 0.104), insulin sensitive index (WMD = 0.42, 95% CI: 0.13-0.72, = 0.004). The total effective ratio of the OG is more effective than CG (RR = 1.33, 95% CI: 1.26-1.40, = 0.000), the significant effective ratio (RR = 1.69, 95% CI: 1.48-1.93, = 0.000). Astragalus may provide specific benefits for T2DM patients as an adjuvant treatment. Nonetheless, the certainty of the evidence and risk of bias fell short of optimal performance, indicating the need for additional clinical research to ascertain potential effects. PROSPERO REGISTRATION NUMBER CRD42022338491.
这项荟萃分析评估了黄芪在治疗 2 型糖尿病（T2DM）患者中的有益作用和潜在不良反应。作者在以下数据库中检索了黄芪治疗 T2DM 患者的随机对照试验：PubMed、Embase、Cochrane 图书馆、中国知识资源整合数据库（CNKI）、万方数据、中国科技期刊数据库（CQVIP）和中国生物医学文献数据库（SinoMed）。两名审查员独立进行了研究选择、数据提取和编码，以及对纳入研究的偏倚风险进行评估。使用 STATA，v.15.1 软件进行标准荟萃分析和适当情况下的荟萃回归。该荟萃分析包含 20 项研究，共计 953 名参与者。与对照组（CG）相比，观察组（OG）降低了空腹血糖（FPG）（WMD=-0.67，95%CI：-1.13∼-0.20，=0.005）、餐后 2 小时血糖（2hPG）（WMD=-0.67（95%CI：-1.13∼-0.20，=0.005）、糖化血红蛋白 A1C（HbA1c）（WMD=-0.93，95%CI：-1.22∼-0.64，=0.000）、胰岛素抵抗的稳态模型评估（HOMA-IR）（WMD=-0.45，95%CI：-0.99∼0.99，=0.104）、胰岛素敏感指数（WMD=0.42，95%CI：0.13-0.72，=0.004）。OG 的总有效率高于 CG（RR=1.33，95%CI：1.26-1.40，=0.000），显效率（RR=1.69，95%CI：1.48-1.93，=0.000）。黄芪作为辅助治疗可能对 T2DM 患者具有特定的益处。然而，证据的确定性和偏倚风险未能达到最佳水平，这表明需要进行更多的临床研究以确定潜在的效果。PROSPERO 注册号 CRD42022338491。
